Innate Pharma S.A. (NASDAQ: IPHA) had its price target lowered by analysts at SVB Leerink LLC from $10.00 to $9.00. They now have an "outperform" rating on the stock.
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma) [Yahoo! Finance]Yahoo! Finance
- Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio [Yahoo! Finance]Yahoo! Finance
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 [Yahoo! Finance]Yahoo! Finance
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024Business Wire